Insulin-like growth factor 1 (IGF-1) alters drug sensitivity of HBL100 human breast cancer cells by inhibition of apoptosis induced by diverse anticancer drugs

Cancer Research

Volumn 57, Issue 13, 1997, Pages 2687-2693

  Dunn, Sandra E ^a   Hardman, Rebecca A ^a   Kari, Frank W ^a   Barrett, J Carl ^a  

^a NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAMPTOTHECIN; COLLAGEN TYPE 4; DNA FRAGMENT; FLUOROURACIL; LAMININ; MATRIGEL; METHOTREXATE; PROTEIN BCL 2; SOMATOMEDIN C; TAMOXIFEN;

APOPTOSIS; ARTICLE; BREAST CANCER; CELL PROLIFERATION; CELL SURVIVAL; DIAGNOSIS; DRUG CYTOTOXICITY; DRUG EFFICACY; EXTRACELLULAR MATRIX; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BLOTTING, NORTHERN; BLOTTING, WESTERN; BREAST NEOPLASMS; CAMPTOTHECIN; CELL SURVIVAL; COLLAGEN; DRUG COMBINATIONS; EXTRACELLULAR MATRIX; FEMALE; FLUOROURACIL; HUMANS; INSULIN-LIKE GROWTH FACTOR I; LAMININ; METHOTREXATE; MICROSCOPY, ELECTRON; PROTEOGLYCANS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; TAMOXIFEN; TIME FACTORS; TUMOR CELLS, CULTURED;

EID: 0030738695     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Eastman, A. Activation of programmed cell death by anticancer agents: cisplatin as a model system. Cancer Cells (Cold Spring Harbor), 2: 275-280, 1990.
2. Boudreau, N., Sympson, C. J., Werb, Z., and Bissell, M. J. Suppression of ICE and apoplosis in mammary epithelial cells by extracellular matrix. Science (Washington DC), 267: 891-893, 1995.
3. Resnicoff, M., Coppola, D., Sell, C., Rubin, R., Ferrone, S., and Baserga, R. Growth inhibition of human melanoma cells in nude mice by antisense strategies to the type 1 insulin-like growth factor receptor. Cancer Res., 34: 4848-4850, 1994.
4. Resnicotf, M., Abraham, D., Yutanawiboonchai, W., Rotman, H., Kajstura, J., Rubin, R., Zoltick, P., and Baserga, R. The insulin-like growth factor I receptor protects tumor cells from apoptosis in vivo. Cancer Res., 55: 2463-2469, 1995.
5. D'Ambrosio, C., Ferber, A., Resnicoff, M., and Baserga, R. A soluble insulin-like growth factor 1 receptor that induces apoptosis of tumor cells in vivo and inhibits tumorigenesis. Cancer Res., 56: 4013-4020, 1996.
6. Harrington, E. A., Bennett, M. R., Fanidi, A., and Evan, G. I. C-myc-induced apoptosis in fibroblasts is inhibited by specific cytokines. EMBO J., 13: 3286-3295, 1994.
7. Sell, C., Baserga, R., and Rubin, R. Insulin-like growth factor 1 (IGF-1) and the IGF-1 receptor prevent etoposide-induced apoptosis. Cancer Res., 55: 2463-2469, 1995.
8. Christofori, G., Naik, P., and Hanuhan, D. A second signal supplied by insulin-like growth factor II in oncogene-induced tumorigenesis. Nature (Lond.), 369: 414-418, 1994.
9. Neuenschwander, S., Schwartz, A., Wood, T. L., Roberts, C. T. J., Henninghausen, L., and LeRoith, D. Involution of the lactating mammary gland is inhibited by the IGF system in transgenic mouse model. J. Clin. Invest., 97: 2225-2232, 1996.
10. Peyrat, J. P., Bonneterre, J., Hecquet, B., Vennin, P., Louchez, M. M., Fournier, C., Lefebvre, J., and Demaille, A. Plasma insulin-like growth factor-1 (IGF-1) concentrations in human breast cancer. Eur. J. Cancer, 29A: 492-497, 1993.
11. Peyrat, J. P., and Bonneterre, J. Type 1 IGF receptor in human breast diseases. Breast Cancer Res. Treat., 22: 59-67, 1992.
12. Yee, D., Paik, S., Lebovic, G. S., Marcus, R. R., Favoni, R. E., Cullen, K. J., Lippman, M. E., and Rosen, N. Analysis of insulin-like growth factor 1 gene expression in malignancy: evidence for a paracrine role in human breast cancer. Mol. Endocrinol., 3: 509-517, 1989.
13. Teixeira, C., Reed, J. C., and Pratt, M. A. C. Estrogen promotes chemotherapeutic drug resistance by a mechanism involving Bcl-2 proto-oncogene expression in human breast cancer cells. Cancer Res., 55: 3902-3907, 1995.
14. Wang, T. T. Y., and Phang, J. M. Effects ot estrogen on apoptotic pathways in human breast cancer cell line MCF-7. Cancer Res., 55: 2487-2489, 1995.
15. Bargou, R. C., Daniel, P. T., Mapara, M. Y., Bommert, K., Wagener, C., Kallinich, B., Royer, H. D., and Dorken, B. Expression of the bcl-2 gene family in normal and malignant breast tissue: low bax-α expression in tumor cells correlates with resistance toward apoptosis. Int. J. Cancer, 60: 854-859, 1995.
16. Krajewski, S., Blomqvist, C., Franssila, K., Krajewska, M., Wasenius, V., Niskanen, E., Nordling, S., and Reed, J. C. Reduced expression of proapoptotic gene bax is associated with poor response rates to combination chemotherapy and shorter survival in women with metastatic breast adenocarcinoma. Cancer Res., 55: 4471-4478, 1995.
17. Wagener, C., Borgou, R. C., Daniel, P. T., Bommert, K., Mapara, M. Y., Rover, H. D., and Dorken, B. Induction of death-promoting gene bax-α sensitizes cultured breast cancer cells to drug-induced apoptosis. Int. J. Cancer, 67: 138-141, 1996.
18. Sakakura, C., Sweeney, E. A., Shirahama, T., Igarashi, Y., Hakomori, S., Nakatani, H., Tsujimoto, H., Imanishi, T., Ohgaki, K., Ohyama, T., Yamazaki, J., Hagiwara, W., Yamaguchi, T., Sawai, K., and Takahashi, T. Overexpression of bax sensitises human breast cancer MCF7 cells to radiation-induced apoptosis. Int. J. Cancer, 67: 101-105, 1996.
19. Ziehe, M., and Gullino, P. Angiogenesis and neoplastic progression in vitro. J. Natl. Cancer Inst., 69: 483-487, 1982.
20. Preston, G. A., Lang, J. E., Maronpot, R. R., and Barrett, J. C. Regulation of apoptosis by low serum in cells of different stages of neoplastic progression: enhanced susceptibility after loss of a senescence gene and decreased suseptibility after loss of a tumor suppressor gene. Cancer Res., 54: 4214-4223, 1994.
21. Dunn, S. E., Hughes, C. A., LeBlanc, G. A., and Cullen, J. M. Overexpression of a P-glycoprotein in hepatocellular carcinomas from woodchuck hepatitis virus-infected woodchucks (Marmota monax). Hepatology, 23: 662-668, 1996.
22. Sambrook, J., Fritsch, E. F., and Maniatis, T. Extraction, purification, and analysis of messenger RNA from eukaryotic cells. In: C. Nolan (ed.), Molecular Cloning: A Laboratory Manual, pp. 7.0-7.53. Cold Sprine Harbor, NY: Cold Spring Harbor Laboratory, 1989.
23. Guler, H. P., Zapf, J., Schmid, C., and Froesch, E. R. Insulin-like growth factors I and II in healthy man: estimates of half-lives and production rates. Acta Endocrinol., 121: 753-758, 1989.
24. Osborne, C. K., Clemmons, D. R., and Arteaga, C. L. Regulation of breast cancer-growth by insulin-like growth factors. J. Steroid Biochem. Mol. Biol., 37: 805-809, 1990.
25. Geier, A., Beery, R., Haimsohn, M., and Karasik, A. Insulin-like growth factor-1 inhibits cell death induced by anticancer drugs in the MCF-7 cells: involvement of growth factors in drug resistance. Cancer Invest., 13: 480-486, 1995.
26. Oltavi, Z., Milliman, C. L., and Korsmeyer, S. J. BCL-2 heterodimerizes in vivo with a conserved homolog, bax, that accelerates programed cell death. Cell, 74: 604-619, 1993.
27. Miyashita, T., Krajewski, S., Krajewska, M., Wang, H. G., Lin, H. K., Hoffman, B., Lieberman, D., and Reed, J. C. Tumor suppressor p53 is a regulator of bcl-2 and bax in gene expression in vitro and in vivo. Oncogene, 9: 1799-1805, 1994.
28. Vanhamme, L., and Szpirer, C. Transforming activity of the human mammary line HBL100 DNA is associated with SV49 large T-antigen genetic information integrated into its genome. Carcinogenesis (Lond.), 9: 653-655, 1988.
29. Mietz, J. A., Unger, T., Huibregtse, J. M., and Howley, P. M. The transcriptional transactivation function of wild-type p53 is inhibited by SV40 large T-antigen and by HPV-16 E6 oneoprotein. EMBO J., 11: 5013-5020, 1992.
30. Cullen, K. J., Smith, H. S., Hill, S., Rasen, N., and Lippman, M. E. Growth factor messenger RNA expression by human breast fibroblasts from benign and malignant lesions. Cancer Res., 51: 4978-4985, 1991.
31. Vignon, F., Prebois, C., and Rochefort, H. Inhibition of breast cancer growth by Suramin. J. Natl. Cancer Inst., 84: 38-42, 1992.
32. Ravera, F., Miglietta, L., Pirani, P., Ferrini, S., and Favoni, R. E. Suramin-induced growth inhibition and insulin-like growth factor I binding blockade in human breast carcinoma cells: potentially related events. Eur. J. Cancer, 29A: 225-230, 1993.
33. Weckbecker, G., Tolesvai, L., Stolz, B., Pollak, M., and Bruns, C. Somatostatin analogue octreotide enhances the antineoplastic effects of tamoxifen and ovariectomy on 7,12-dimethylbenz(a)anthracene-induced rat mammary carcinomas. Cancer Res., 54: 6334-6337, 1994.
34. Friedl, A., Jordon, J. C. and Pollak, M. Suppression of serum insulin-like growth factor-1 levels in breast cancer patients during adjuvant tamoxifen therapy. Eur. J. Cancer, 29A: 1368-1372, 1993.
35. Kazer, R. R. Insulin resistance, insulin-like growth factor I, and breast cancer: a hypothesis. Int. J. Cancer, 62: 403-406, 1995.
36. Neuenschwander, S., Roberts, C. T., and LeRoith, D. Growth inhibition of MCF-7 breast cancer cells by stable expression of an insulin-like growth factor I receptor antisense ribonucleic acid. Endocrinology, 136: 4298-4303, 1995.